Oxygen Biotherapeutics to Present at 23rd Annual Piper Jaffray Healthcare Conference


MORRISVILLE, N.C., Nov. 22, 2011 (GLOBE NEWSWIRE) -- Oxygen Biotherapeutics, Inc. (Nasdaq:OXBT) (SIX:OXBT) today announced that Chief Financial Officer and Interim CEO Michael Jebsen will present at the upcoming 23rd Annual Piper Jaffray Healthcare Conference on November 30, 2011 at 1:30 pm ET, at The New York Palace Hotel in New York City.

A live audio broadcast of the company's presentation will be accessible on the company's website, www.oxybiomed.com , under the "Investor" tab. In addition, a replay of the presentation will be available for a limited time on the website.

About Oxygen Biotherapeutics, Inc.

Headquartered in Morrisville, NC, Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed proprietary perfluorocarbon (PFC) therapeutic oxygen carrier products that are being formulated for both intravenous and topical delivery. The company is focused on PFC-based oxygen carriers for use in traumatic brain injury, decompression sickness, wound and dermatologic indications. In the cosmetic area, the company has commercialized its DERMACYTE® line of oxygen-rich skin care products. See www.oxybiomed.com, or www.DermacyteUS.com for more information.

The Oxygen Biotherapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7277

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include the management transition and expansion of research and development of the Oxycyte® product line, including the timing of the introduction of these new products. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the company's control that could lead to delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current quarterly report filed on Form 10-Q on September 19, 2011, and the annual report on Form 10-K filed on July 15, 2011. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.


            

Coordonnées